Phase 2 Trial of AGEN2034 (anti-PD-1) as a Monotherapy of Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

The research study is being conducted to study the PD-1 antibody, AGEN2034 alone, or in combination with the CTLA-4 antibody, AGEN1884, in women with recurrent cervical cancer. Subjects will be asked to complete the following research procedures: 12 lead electrocardiogram (ECG) and evaluation of heart function (to determine heart health). Routine blood tests for health and safety reasons (about 1 tablespoon) to measure how many white blood cells, red blood cells, and platelets you have, the function of your liver, kidneys, thyroid and to measure the ability of your blood to clot. Urinalysis. Serum pregnancy test (if you are a woman of childbearing potential). Tumor Imaging Computed Tomography (CT) scan (not required if performed within 21 days prior to the first dose of trial treatment). Collection of stored tumor specimen from previous biopsy to test for PD-L1 expression later. If stored tumor specimen is not available, a fresh biopsy will be required.

You may be eligible for this study if you meet the following criteria:

• Conditions: cervical cancer
• Age: 99 years or below
• Gender: All